Tags

Type your tag names separated by a space and hit enter

Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Prostate. 2003 Feb 01; 54(2):125-32.P

Abstract

BACKGROUND

Insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) play an important role in regulation of prostate cancer cell growth. We studied the prognostic significance of serum IGF-1 and IGFBP-3 levels, and IGF-1/prostate-specific antigen (PSA) and IGFBP-3/PSA ratios in patients with prostate cancer.

METHODS

Serum levels of IGF-1, IGFBP-3, and PSA were determined in 112 patients diagnosed with prostate cancer. Serum samples from 32 patients with histologically confined benign prostatatic hyperplasia (BPH) served as control.

RESULTS

Serum IGF-1 levels were significantly higher in advanced prostate cancer (n = 84) than in BPH patients (P < 0.01). IGFBP-3 levels were significantly lower in patients with advanced prostate cancer than in localized tumor (n = 28) or BPH (P < 0.05, each). Univariate analysis showed that serum PSA, IGF-1/PSA ratio, IGFBP-3/PSA ratio, T, N and M classifications correlated significantly with relapse-free survival of advanced prostate cancer patients treated with hormonal therapy. Multivariate analysis identified IGFBP-3/PSA ratio as the only significant variable for relapse-free survival (odds ratio 5.81, 95% CI 1.57-21.51). IGFBP-3/PSA ratio was also an independent predictor of cause-specific survival (stepwise analysis, odds ratio 4.86, P < 0.01).

CONCLUSIONS

Our results suggested that IGFBP-3/PSA ratio might be a useful prognostic marker of advanced prostate cancer.

Authors+Show Affiliations

Department of Urology, Nagasaki University School of Medicine, Nagasaki, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

12497585

Citation

Miyata, Yasuyoshi, et al. "Serum Insulin-like Growth Factor Binding Protein-3/prostate-specific Antigen Ratio Is a Useful Predictive Marker in Patients With Advanced Prostate Cancer." The Prostate, vol. 54, no. 2, 2003, pp. 125-32.
Miyata Y, Sakai H, Hayashi T, et al. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate. 2003;54(2):125-32.
Miyata, Y., Sakai, H., Hayashi, T., & Kanetake, H. (2003). Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. The Prostate, 54(2), 125-32.
Miyata Y, et al. Serum Insulin-like Growth Factor Binding Protein-3/prostate-specific Antigen Ratio Is a Useful Predictive Marker in Patients With Advanced Prostate Cancer. Prostate. 2003 Feb 1;54(2):125-32. PubMed PMID: 12497585.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. AU - Miyata,Yasuyoshi, AU - Sakai,Hideki, AU - Hayashi,Tomayoshi, AU - Kanetake,Hiroshi, PY - 2002/12/24/pubmed PY - 2003/2/13/medline PY - 2002/12/24/entrez SP - 125 EP - 32 JF - The Prostate JO - Prostate VL - 54 IS - 2 N2 - BACKGROUND: Insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) play an important role in regulation of prostate cancer cell growth. We studied the prognostic significance of serum IGF-1 and IGFBP-3 levels, and IGF-1/prostate-specific antigen (PSA) and IGFBP-3/PSA ratios in patients with prostate cancer. METHODS: Serum levels of IGF-1, IGFBP-3, and PSA were determined in 112 patients diagnosed with prostate cancer. Serum samples from 32 patients with histologically confined benign prostatatic hyperplasia (BPH) served as control. RESULTS: Serum IGF-1 levels were significantly higher in advanced prostate cancer (n = 84) than in BPH patients (P < 0.01). IGFBP-3 levels were significantly lower in patients with advanced prostate cancer than in localized tumor (n = 28) or BPH (P < 0.05, each). Univariate analysis showed that serum PSA, IGF-1/PSA ratio, IGFBP-3/PSA ratio, T, N and M classifications correlated significantly with relapse-free survival of advanced prostate cancer patients treated with hormonal therapy. Multivariate analysis identified IGFBP-3/PSA ratio as the only significant variable for relapse-free survival (odds ratio 5.81, 95% CI 1.57-21.51). IGFBP-3/PSA ratio was also an independent predictor of cause-specific survival (stepwise analysis, odds ratio 4.86, P < 0.01). CONCLUSIONS: Our results suggested that IGFBP-3/PSA ratio might be a useful prognostic marker of advanced prostate cancer. SN - 0270-4137 UR - https://www.unboundmedicine.com/medline/citation/12497585/Serum_insulin_like_growth_factor_binding_protein_3/prostate_specific_antigen_ratio_is_a_useful_predictive_marker_in_patients_with_advanced_prostate_cancer_ L2 - https://doi.org/10.1002/pros.10175 DB - PRIME DP - Unbound Medicine ER -